Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Tesamorelin

Tesamorelin is a synthetic growth-hormone-releasing factor analogue. Salt, vial strength, excipients, and delivery system matter. Labeled-product trials support the specific approved indication; the reviewed records do not support general weight-loss, anti-aging, or performance claims.

Aliases reviewed
Tesa, EGRIFTA, Tesamorelin acetate
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
Not rated
Animal/cell
Not rated
Approved medicine
Approved product existsSpecific approved products in Canada and the U.S.; a catalogue vial is not one of them.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. It activates the GHRH receptor and is studied through growth-hormone and IGF-1 signaling and metabolic outcomes.

Identity

Tesamorelin is a synthetic growth-hormone-releasing factor analogue. Salt, vial strength, excipients, and delivery system matter.

Biological mechanism or research interest

It activates the GHRH receptor and is studied through growth-hormone and IGF-1 signaling and metabolic outcomes.

Verified approved human uses

Health Canada records EGRIFTA 2 mg/vial tesamorelin, and FDA labels EGRIFTA WR 11.6 mg/vial, to reduce excess abdominal fat in adults with HIV-associated lipodystrophy under labeled conditions. These products and strengths are not interchangeable with a 10 mg catalogue vial.

Investigational human evidence

Labeled-product trials support the specific approved indication; the reviewed records do not support general weight-loss, anti-aging, or performance claims.

Claims about ordinary obesity, muscle gain, or rejuvenation extend beyond the labeled evidence reviewed.

Human versus animal or cell evidence

Mechanistic GH/IGF-1 observations do not substitute for clinical outcomes in the approved population.

Limitations and known risks

Approved labels describe glucose intolerance, elevated IGF-1, fluid retention, hypersensitivity, and malignancy-related precautions. Catalogue-material quality is unverified.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.